T. Rowe Price Associates
NRIX icon

T. Rowe Price Associates’s Nurix Therapeutics NRIX Stock Holding History

T. Rowe Price Associates’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132M Buy
5,436,587
+2,146,354
+65% +$36.6M 0.01% 618
2026
Q1 		$51M Buy
3,290,233
+41,872
+1% +$694K 0.01% 764
2025
Q4 		$61.6M Buy
3,248,361
+2,149,268
+196% +$30.9M 0.01% 746
2025
Q3 		$10.2M Sell
1,099,093
-1,934,751
-64% -$20.1M ﹤0.01% 1225
2025
Q2 		$34.6M Buy
3,033,844
+120,476
+4% +$1.3M ﹤0.01% 829
2025
Q1 		$34.6M Sell
2,913,368
-93,959
-3% -$1.57M ﹤0.01% 824
2024
Q4 		$56.7M Sell
3,007,327
-61,634
-2% -$1.41M 0.01% 719
2024
Q3 		$69M Buy
3,068,961
+233,842
+8% +$5.3M 0.01% 660
2024
Q2 		$59.2M Buy
2,835,119
+638,950
+29% +$9.95M 0.01% 670
2024
Q1 		$32.3M Sell
2,196,169
-193,797
-8% -$2.08M ﹤0.01% 842
2023
Q4 		$24.7M Buy
2,389,966
+11,988
+0.5% +$82.2K ﹤0.01% 906
2023
Q3 		$18.7M Sell
2,377,978
-1,895
-0.1% -$17.3K ﹤0.01% 932
2023
Q2 		$23.8M Sell
2,379,873
-204,878
-8% -$2.09M ﹤0.01% 894
2023
Q1 		$23M Sell
2,584,751
-668,985
-21% -$6.97M ﹤0.01% 885
2022
Q4 		$35.7M Sell
3,253,736
-352,616
-10% -$4.25M 0.01% 758
2022
Q3 		$47M Sell
3,606,352
-1,014,471
-22% -$16.1M 0.01% 666
2022
Q2 		$58.5M Sell
4,620,823
-185,466
-4% -$2.1M 0.01% 828
2022
Q1 		$67.3M Sell
4,806,289
-64,795
-1% -$1.15M 0.01% 862
2021
Q4 		$141M Buy
4,871,084
+152,207
+3% +$4.61M 0.01% 658
2021
Q3 		$141M Buy
4,718,877
+667,399
+16% +$20.6M 0.01% 660
2021
Q2 		$107M Buy
4,051,478
+957,773
+31% +$28.1M 0.01% 755
2021
Q1 		$96.2M Buy
3,093,705
+2,502,069
+423% +$94.7M 0.01% 793
2020
Q4 		$19.5M Buy
591,636
+28,890
+5% +$957K ﹤0.01% 1233
2020
Q3 		$19.6M Buy
+562,746
New +$14.2M ﹤0.01% 1160

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

T. Rowe Price Associates's NRIX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Nurix Therapeutics (NRIX) stake by 65% in Q2 2026, buying an estimated $36.6M and bringing the position to 5,436,587 shares worth $132M. The position accounts for 0.01% of the portfolio, ranked #618.

T. Rowe Price Associates first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $141M in Q3 2021. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • T. Rowe Price Associates held 5,436,587 shares of Nurix Therapeutics worth $132M as of Q2 2026.
  • T. Rowe Price Associates bought 2,146,354 Nurix Therapeutics shares in Q2 2026, an estimated $36.6M.
  • Nurix Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #618 holding.
  • T. Rowe Price Associates first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • T. Rowe Price Associates's Nurix Therapeutics position peaked at $141M in Q3 2021.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.